---
title: "PDS Biotechnology Corp reports results for the quarter ended June 30 - Earnings Summary"
description: "PDS Biotechnology Corp reported a quarterly adjusted loss of 21 cents per share for the quarter ended June 30, an improvement from a loss of 23 cents in the same quarter last year. The company reporte"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252881954.md"
published_at: "2025-08-13T13:31:49.000Z"
---

# PDS Biotechnology Corp reports results for the quarter ended June 30 - Earnings Summary

> PDS Biotechnology Corp reported a quarterly adjusted loss of 21 cents per share for the quarter ended June 30, an improvement from a loss of 23 cents in the same quarter last year. The company reported a total loss of $9.43 million with zero revenue. Analysts had expected a loss of 23 cents per share. PDS shares fell 7.5% this quarter and 24.5% year-to-date. The average analyst rating is "buy" with a 12-month price target of $5.00, indicating a potential upside of 75.4% from the last closing price of $1.23.

-   PDS Biotechnology Corp (PDSB.OQ) reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -23 cents. The mean expectation of three analysts for the quarter was for a loss of 23 cents per share. Wall Street expected results to range from -25 cents to -22 cents per share.
-   Reported revenue was zero​; analysts expected zero.
-   PDS Biotechnology Corp’s reported EPS for the quarter was a loss of 21 cents​.
-   The company reported a quarterly loss of $9.43 million.
-   PDS Biotechnology Corp shares had fallen by 7.5% this quarter and lost 24.5% so far this year. FORECAST CHANGES
-   The mean earnings estimate of analysts had risen by about 5.4% in the last three months.​
-   In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS
-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 3 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.” The average consensus recommendation for the biotechnology & medical research peer group is also “buy”
-   Wall Street’s median 12-month price target for PDS Biotechnology Corp is $5.00, about 75.4% above its last closing price of $1.23 This summary was machine generated from LSEG data August 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

### MISSED

Jun. 30 2025 -0.23 -0.21 Beat

Mar. 31 2025 -0.25 -0.21 Beat

Dec. 31 2024 -0.28 -0.21 Beat

Sep. 30 2024 -0.28 -0.29 Missed

### Related Stocks

- [PDSB.US - PDS Biotechnology](https://longbridge.com/en/quote/PDSB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| PDS Biotech Reports Promising Phase 2 Results for PDS01ADC in Metastatic Prostate Cancer | PDS Biotechnology Corporation has reported promising Phase 2 results for its investigational drug PDS01ADC in treating m | [Link](https://longbridge.com/en/news/273998506.md) |
| PDS Biotechnology Receives Notice of Allowance for New U.S. Patent Covering PDS0101 Technology | PDS Biotechnology Corporation has received a Notice of Allowance from the U.S. Patent Office for its lead asset, PDS0101 | [Link](https://longbridge.com/en/news/273381997.md) |
| PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update | Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metas | [Link](https://longbridge.com/en/news/265742537.md) |
| PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering \| PDSB Stock News | PDS Biotechnology Corporation announced a registered direct offering of up to $11.1 million, consisting of 5.8 million s | [Link](https://longbridge.com/en/news/265394757.md) |
| PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025 | PDS Biotechnology Corporation reported positive clinical data for its HPV16-targeted immunotherapy PDS0101 and immunocyt | [Link](https://longbridge.com/en/news/265168647.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.